加味四妙散治疗原发性肾病综合征湿热型的临床研究
摘要
目的：观察在西医基础治疗上予加味四妙散治疗原发性肾病综合征湿热型的临床疗效,探讨中西医结合治疗本病的优势和可行性,以及为进一步改良及推广配方打下基础。
方法：本研究收集原发性肾病综合征患者符合中医湿热证者50例,随机分为2组,实验组、对照组各25例。对照组予免疫抑制、降蛋白尿等西医基础治疗,实验组在西医基础治疗上加用加味四妙散,疗程为一个月。观察临床症状、体征及实验室检查指标的变化,并对症状及体征进行量化评分,作出疗效评价。
结果：湿热证中医量化评分：实验组显效率56%、有效率36%,总有效率92%；对照组原有湿热症状基本无变化或加重。实验组用药后积分与用药前积分相比具有显著的统计学意义(p<0.01)。实验组和对照组在提高原发性肾病综合征缓解率方面无显著性差异；与治疗组相比,实验组降低蛋白尿与升高血清白蛋白效果稍好,但统计学无显著性差异。
结论：加味四妙散配合西医基础治疗原发性肾病综合征湿热型,能显著改善患者肢体困重、口粘、口苦等湿热临床表现,从而显示出中西医结合治疗本病的优势,是否有助于提高原发性肾病综合征缓解率有待大样本的进一步研究。
Objective:To investigate the effect of Jia-wei-si-miao Powder treating idiopathic nephrotic syndrome of damp-heat on the basis of western medicine treatment. To explore the advantages and feasibility of combining traditional Chinese and western medicine treating idiopathic nephrotic syndrome and lay the foundation for further improvement.
Methods:50 patients with idiopathic nephrotic syndrome of damp-heat were divided into 2 groups at random, each group is 25 cases. The control group were treated with basic medicine, while the experimental treatment group were treated with basic medicine and Jia-wei-si-miao Powder. The course of treatment is 1 month. We would observe the subjects of laborary examination before and after experiment, recorded the change of patients' clinical symptoms, at last observed the curative effects.
Results:The obviously effective ratio of Jia-wei-si-miao Powder treating group is 56%, the effective ratio 36%,the total effective ratio is 92%; The original symptoms of damp-heat were basically unchanged or worsen. In the Jia-wei-si-miao Powder treating group, it is significantly different between the scores of pro-treatment and post-treatment (p<0.01). There is no significant difference in the remission of idiopathic nephrotic syndrome.
Conclusion:The treatment of idiopathic nephrotic syndrome of damp-heat with basic medicine and Jia-wei-si-miao Powder can significantly improve the clinical performance caused by damp-heat. Thus the advantage of combining traditional Chinese medicine and western medicine in the treatment of the disease can be showed.
方法：本研究收集原发性肾病综合征患者符合中医湿热证者50例,随机分为2组,实验组、对照组各25例。对照组予免疫抑制、降蛋白尿等西医基础治疗,实验组在西医基础治疗上加用加味四妙散,疗程为一个月。观察临床症状、体征及实验室检查指标的变化,并对症状及体征进行量化评分,作出疗效评价。
结果：湿热证中医量化评分：实验组显效率56%、有效率36%,总有效率92%；对照组原有湿热症状基本无变化或加重。实验组用药后积分与用药前积分相比具有显著的统计学意义(p<0.01)。实验组和对照组在提高原发性肾病综合征缓解率方面无显著性差异；与治疗组相比,实验组降低蛋白尿与升高血清白蛋白效果稍好,但统计学无显著性差异。
结论：加味四妙散配合西医基础治疗原发性肾病综合征湿热型,能显著改善患者肢体困重、口粘、口苦等湿热临床表现,从而显示出中西医结合治疗本病的优势,是否有助于提高原发性肾病综合征缓解率有待大样本的进一步研究。
Objective:To investigate the effect of Jia-wei-si-miao Powder treating idiopathic nephrotic syndrome of damp-heat on the basis of western medicine treatment. To explore the advantages and feasibility of combining traditional Chinese and western medicine treating idiopathic nephrotic syndrome and lay the foundation for further improvement.
Methods:50 patients with idiopathic nephrotic syndrome of damp-heat were divided into 2 groups at random, each group is 25 cases. The control group were treated with basic medicine, while the experimental treatment group were treated with basic medicine and Jia-wei-si-miao Powder. The course of treatment is 1 month. We would observe the subjects of laborary examination before and after experiment, recorded the change of patients' clinical symptoms, at last observed the curative effects.
Results:The obviously effective ratio of Jia-wei-si-miao Powder treating group is 56%, the effective ratio 36%,the total effective ratio is 92%; The original symptoms of damp-heat were basically unchanged or worsen. In the Jia-wei-si-miao Powder treating group, it is significantly different between the scores of pro-treatment and post-treatment (p<0.01). There is no significant difference in the remission of idiopathic nephrotic syndrome.
Conclusion:The treatment of idiopathic nephrotic syndrome of damp-heat with basic medicine and Jia-wei-si-miao Powder can significantly improve the clinical performance caused by damp-heat. Thus the advantage of combining traditional Chinese medicine and western medicine in the treatment of the disease can be showed.
引文
[1]周仲瑛.中医内科学[M].北京：中国中医药出版社,2006.346.
[2]叶任高,李幼姬,刘冠贤.临床肾脏病学[M].北京：人民卫生出版社,2007.164-165.
[3]叶任高,陆再英,等.内科学[M].北京：人民卫生出版社,2004.508,511,514,516.
[4]邓中甲,方剂学[M].北京：中国中医药出版社,2005.303.
[5]中华人民共和国国家标准中医临床诊疗术语证候部分.国家技术监督局,1997,03,04
[6]郑筱英.任德权,等.《中药新药临床研究指导原则》[M].中国中医药科技出版社,2002年5月
[7]中华人民共和国国家标准中医临床诊疗术语.国家中医药管理局科技教育司
[8]叶任高,陈裕盛,方敬爱.肾病诊断与治疗及疗效标准专题讨论纪要[J].中国中西医结合肾病杂志,2003,4(6)：355457.
[9]傅文录,王天明,田献忠等.肾脏病(专科专病名医临证经验丛书)[M].北京：人民卫生出版社,2002.180.
[10]陈以平.肾病的辨证与辨病治疗[M].北京：人民卫生出版社,2003.58.
[11]冯天保.谢桂权教授治疗难治性肾病综合征经验撷菁[J].中医药学刊.2005,23(9)：1574.
[12]闵存云.叶任高教授治疗肾病综合征的临床经验[J].中国中西医结合肾病杂志,2002,3(7)：378.
[13]毛以林.刘新祥教授治疗原发性肾病综合征经验[J].中医药通报,2004,3(4)：31.
[14]米杰,马宝良.四妙散在泌尿系统疾病中的临床应用[J].中国中西医结合肾病杂志,2009,10(12)：1094.
[15]张道友,叶任高,李幼姬,等.成人原发性肾病综合征临床及实验系列研究成果综述[J].中山医科大学学报,1999,20(2)：85
[16]李灵辉,张喜奎.按“四气”划分西药属性的可行性初探[J].湖北中医杂志,2005,27(1)：5-7.
[17]甘宁峰,黄贵华.中医对糖皮质激素类药物的认识[J]。广西中医药,2008,31(2)：40-41.
[18]张锡纯.医学衷中参西录[M].石家庄：河北科技出版社,1985：14.
[19]聂莉芳,陈荣源.难治性肾病综合征中西医结合治疗的研究进展[J].中国中西医结合肾病杂志,2006,7(7)：424
[20]刘刚,马序竹,邹万忠,等.肾活检患者肾脏病构成十年对比分析[J].临床内科杂志,2004,21：834-838.
[21]Vriesendorp R,de Zeeuw D,de jong PE,et al.Reduction of urinary protein and prostaglandin E2 excretion in the nephritic syndrome by non-steroid anti-inflammatory drugs[J].Clin Nephrol,1986,25:105-110.
[22]Heeg JE,de jong PE,van der Hem GK,et al.Reduction of proteinuria by angiotensin converting enzyme inhibition[J].Kidney Int,1987,32:78-83.
[23]Ballmer PE,Weber BK,Roy Chaudhury P,et al.Elevation of albumin synthesis rates in nephritic patients measured with [1-13C] leucinr[J].Kidney Int,1992,41:132-138.
[24]李丽英,于宏,潘辑圣,等.黄芪与当归对肾病综合征患者总体蛋白质代谢的影响[J].中华内科杂志,1995,34：670-672.
[25]Schultze G,Ahuja S,Faber U,et al.Gastrointestinal protein loss in the nephritic syndrome with 51Cr-albumin[J].Nephron,1980,25:227-230.
[26]Schrier RW, Fassett RG. A critique of the overfill hypothesis of sodium and water retention in the nephritic syndrome[J]. Kidney Int,1998,53:1111-1117.
[27]Vande Walle JG,Donckerwolcke RA,van Isselt JW,et al.Volume regulation in children with early relapse of minimal-change nephrosis with or without hypovolaemic symptoms[J].Lancet,1995,346:148-152.
[28]Bernard DB.Extrarenal complications of the nephritic syndrome[J].Kidney Int,1988,33:1184-1202.
[29]Short CD,Durtington PN,Mallick NP,et al.Serum and urinary high-density lipoprotions in glomerular disease with proteinuria[J].Kidney Int,1986,29: 1224-1228.
[30]吕燕,邱全瑛.黄柏对小鼠DTH及其体内几种细胞因子的影响[J].北京中医药大学学报,1999,22(6)：48.
[31]余上才，章育正.牛膝多糖抗肿瘤作用及免疫机制实验研究[J].中华肿瘤杂志：1995,17(4)：275.
[32]向道斌,李晓玉.牛膝多糖对小鼠腹腔巨噬细胞产生的白细胞介素-1和肿瘤坏死因子的影响[J].中国药理学报,1993,14(4)：332.
[33]戴伟礼,李根池.小鼠甲醛致痛模型筛选中药牛膝的镇痛作用[J].中成药,1989,11(]0)：29.
[34]苗明三.薏苡仁多糖对环磷酸酰胺致免疫抑制小鼠免疫功能的影响[J].中国医药学报,2002,30(5).
[35]史玉芬,郑延彬.牛膝抗炎、抗菌作用的研究[J].中药通报,1988,13(7)：44.
[36]马子密,傅延龄.历代本草药性汇解[M].中国医药科技出版社,2002.
[37]陈长勋,李廷利,王树荣,等.中药药理学[M].上海科学技术出版社,2007.
[38]延卫东,王瑞君,何淡,等.黄芩苷药理作用研究进展[J].陕西中医.2002,23(12)：1127-1129.
[39]王玮,呈莹瑶,卢岩,等.野黄芩甙抗炎作用的实验研究[J].中国医科大学学报.2003,32(6)：503-504.
[40]Chen ZY,Su YL,Lac CW.et al.Endothelium dependent contraction and direct relaxation induced by baicalin in rat mesenteric artery[J].Eur J pharmarcol, 1999,374(1):41.
[41]于永芳,高瑞峰,李沈明.黄芩茎叶总黄酮对动脉粥术硬化早期病理改变的影响.中草药[J].2003,34(11)：1033-1035
[42]董昆山.现代临床中药学[M].中国中医药出版社,1998：533.
[43]阮金兰,赵钟祥,曾庆忠.赤芍化学成分和药理作用的研究进展[J].中国药理学通报,2003,19(9)：965-970.
[44]瞿佐发.赤芍的最新研究进展[J].时珍国医国药,2003,14(8)：310-311.
[45]Bhardwaj DK,Singh R.CA,1998,88:19048k.
[46]黄颂敏,刘先荣.肾脏疾病鉴别诊断与治疗学[M].人民军医出版社,2006.35.
[47]杨宝峰,苏定冯.药理学[M].人民卫生出版社,2006.216,283.
[48]陈香美,等.糖皮质激素治疗肾脏病的专家共识(第一版).2008年11月,北京.
[49]张宇明,闻家柱.大剂量谷胱甘肽治疗雷公藤多甙致药物性肝损害15例[J].中华现代内科学杂志.2005,2(3)：221.
[1]刘刚,马序竹,邹万忠,等.肾活检患者肾脏病构成十年对比分析[J].临床内科杂志,2004,21：834-838.
[2]Vriesendorp R,de Zeeuw D,de jong PE,et al.Reduction of urinary protein and prostaglandin E2 excretion in the nephritic syndrome by non-steroid antiinflammat-ory drugs[J].Clin Nephrol,1986,25:105-110.
[3]Heeg JE,de jong PE,van der Hem GK,et al.Reduction of proteinuria by angiotensin converting enzyme inhibition.Kidney Int[J],1987,32:78-83.
[4]Ballmer PE,Weber BK,Roy Chaudhury P,et al.Elevation of albumin synthesis rates in nephritic patients measured with [1-13C] leucinr[J].Kidney Int,1992,41:132-138.
[5]李丽英,于宏,潘辑圣,等.黄芪与当归对肾病综合征患者总体蛋白质代谢的影响[J].中华内科杂志,1995,34：670-672.
[6]Schultze G,Ahuja S,Faber U,et al.Gastrointestinal protein loss in the nephritic syndrome with 51Cr-albumin[J].Nephron,1980,25:227-230.
[7]Schrier RW,Fassett RG.A critique of the overfill hypothesis of sodium and water retention in the nephritic syndrome[J]. Kidney Int,1998,53:1111-1117.
[8]Vande Walle JG,Donckerwolcke RA,van Isselt JW,et al.Volume regulation in children with early relapse of minimal-change nephrosis with or without hypovol-aemic symptoms[J].Lancet,1995,346:148-152.
[9]Bernard DB.Extrarenal complications of the nephritic syndrome[J].Kidney Int,1988, 33:1184-1202.
[10]Short CD,Durtington PN,Mallick NP,et al.Serum and urinary highdensity lipoprotions in glomerular disease with proteinuria[J].Kidney Int,1986,29:1224-1228.
[11]陈香美,等.糖皮质激素治疗肾脏病的专家共识(第一版).2008年11月,北京.
[12]杨藻宸.医用药理学[M].北京：人民卫生出版社,2005,355-695.
[13]周仲瑛.中医内科学[M].北京：中国中医药出版社,2006.345-351
[14]李杰.肾性蛋白尿治疗刍议[J],长春中医学院学报,1995,11(12)：19.
[15]蔡红凯,李玉婷,乐才文.四妙散在肾病中的运用[J].中国中医急症,2006,15(10)：1162.
[16]于怀庆.辨证治疗慢性肾炎蛋白尿40例[J].陕西中医,2000,21(4)：155.
[17]师晶丽.肾小球疾病中医辨证分型与血脂关探讨[J].贵阳中医学院学报,1995,20(1)：32-33.
[18]管鹏声.肾病综合征治疗经验[J],云南中医学院学报,1996,19(4)：34.
[19]孙环宇.五子衍宗丸加减治疗肾病蛋白尿[J],山东中医杂志,2001,20(4)：249.
[20]张志忠.仙黄散治疗难治性肾病综合征蛋白尿[J],中国中医杂志,2002,11(3)：221.
[21]韩履祺,王琴.难治性肾病综合征从肝论治[J].2000,(2)：75.
[22]石景凉.中医药消除肾病综合征蛋白尿六法[J],河南中医,1999,19(3)：3.
[23]叶任高,李幼姬,刘冠贤,等.临床肾脏病学[M].北京：人民卫生出版社,2007.164-165.
[24]李月红.中西医结合治疗原发性肾病综合征的思路.2009年9月,天津.
[25]张道友,叶任高,李幼姬,等.成人原发性肾病综合征临床及实验系列研究成果综述[J].中山医科大学学报,1 999,20(2)：85.
[26]杨倩春.杨霓芝教授治疗难治性肾病综合征的临床经验[J].中国中两医结合肾病杂志,2003,4(9)：500-502.
[27]谢昆,叶任高,陈志英.中西医治疗成人复发性肾病综合征疗效观察[J].现代诊断与治疗,1998,9(1)：17-21.
[28]顾美华,李永玉,李小伟.中医中药为主治疗难治性肾病综合征60例[J].国医论坛,1992,7(2)：23-24.
[29]刘宏伟,时振声,林秀彬.难治性‘肾病综合征的中医治疗体会-附30例临床分析[J].天津中医,1992,(2)：2-3.
[30]赵兴兰,余仁欢.辨证分型治疗难治性肾病综合征[J].吉林中医药,1995,(3)：8-9.
[31]武俊斌,顾秀琰.戴恩来教授治疗难治性肾病综合征经验.亚太传统医药[J].2007,(1)：52-53.
[32]米杰,马宝良.四妙散在泌尿系统疾病中的临床应用[J].中国中西医结合肾病杂志,2009,10(12)：1094.
[2]叶任高,李幼姬,刘冠贤.临床肾脏病学[M].北京：人民卫生出版社,2007.164-165.
[3]叶任高,陆再英,等.内科学[M].北京：人民卫生出版社,2004.508,511,514,516.
[4]邓中甲,方剂学[M].北京：中国中医药出版社,2005.303.
[5]中华人民共和国国家标准中医临床诊疗术语证候部分.国家技术监督局,1997,03,04
[6]郑筱英.任德权,等.《中药新药临床研究指导原则》[M].中国中医药科技出版社,2002年5月
[7]中华人民共和国国家标准中医临床诊疗术语.国家中医药管理局科技教育司
[8]叶任高,陈裕盛,方敬爱.肾病诊断与治疗及疗效标准专题讨论纪要[J].中国中西医结合肾病杂志,2003,4(6)：355457.
[9]傅文录,王天明,田献忠等.肾脏病(专科专病名医临证经验丛书)[M].北京：人民卫生出版社,2002.180.
[10]陈以平.肾病的辨证与辨病治疗[M].北京：人民卫生出版社,2003.58.
[11]冯天保.谢桂权教授治疗难治性肾病综合征经验撷菁[J].中医药学刊.2005,23(9)：1574.
[12]闵存云.叶任高教授治疗肾病综合征的临床经验[J].中国中西医结合肾病杂志,2002,3(7)：378.
[13]毛以林.刘新祥教授治疗原发性肾病综合征经验[J].中医药通报,2004,3(4)：31.
[14]米杰,马宝良.四妙散在泌尿系统疾病中的临床应用[J].中国中西医结合肾病杂志,2009,10(12)：1094.
[15]张道友,叶任高,李幼姬,等.成人原发性肾病综合征临床及实验系列研究成果综述[J].中山医科大学学报,1999,20(2)：85
[16]李灵辉,张喜奎.按“四气”划分西药属性的可行性初探[J].湖北中医杂志,2005,27(1)：5-7.
[17]甘宁峰,黄贵华.中医对糖皮质激素类药物的认识[J]。广西中医药,2008,31(2)：40-41.
[18]张锡纯.医学衷中参西录[M].石家庄：河北科技出版社,1985：14.
[19]聂莉芳,陈荣源.难治性肾病综合征中西医结合治疗的研究进展[J].中国中西医结合肾病杂志,2006,7(7)：424
[20]刘刚,马序竹,邹万忠,等.肾活检患者肾脏病构成十年对比分析[J].临床内科杂志,2004,21：834-838.
[21]Vriesendorp R,de Zeeuw D,de jong PE,et al.Reduction of urinary protein and prostaglandin E2 excretion in the nephritic syndrome by non-steroid anti-inflammatory drugs[J].Clin Nephrol,1986,25:105-110.
[22]Heeg JE,de jong PE,van der Hem GK,et al.Reduction of proteinuria by angiotensin converting enzyme inhibition[J].Kidney Int,1987,32:78-83.
[23]Ballmer PE,Weber BK,Roy Chaudhury P,et al.Elevation of albumin synthesis rates in nephritic patients measured with [1-13C] leucinr[J].Kidney Int,1992,41:132-138.
[24]李丽英,于宏,潘辑圣,等.黄芪与当归对肾病综合征患者总体蛋白质代谢的影响[J].中华内科杂志,1995,34：670-672.
[25]Schultze G,Ahuja S,Faber U,et al.Gastrointestinal protein loss in the nephritic syndrome with 51Cr-albumin[J].Nephron,1980,25:227-230.
[26]Schrier RW, Fassett RG. A critique of the overfill hypothesis of sodium and water retention in the nephritic syndrome[J]. Kidney Int,1998,53:1111-1117.
[27]Vande Walle JG,Donckerwolcke RA,van Isselt JW,et al.Volume regulation in children with early relapse of minimal-change nephrosis with or without hypovolaemic symptoms[J].Lancet,1995,346:148-152.
[28]Bernard DB.Extrarenal complications of the nephritic syndrome[J].Kidney Int,1988,33:1184-1202.
[29]Short CD,Durtington PN,Mallick NP,et al.Serum and urinary high-density lipoprotions in glomerular disease with proteinuria[J].Kidney Int,1986,29: 1224-1228.
[30]吕燕,邱全瑛.黄柏对小鼠DTH及其体内几种细胞因子的影响[J].北京中医药大学学报,1999,22(6)：48.
[31]余上才，章育正.牛膝多糖抗肿瘤作用及免疫机制实验研究[J].中华肿瘤杂志：1995,17(4)：275.
[32]向道斌,李晓玉.牛膝多糖对小鼠腹腔巨噬细胞产生的白细胞介素-1和肿瘤坏死因子的影响[J].中国药理学报,1993,14(4)：332.
[33]戴伟礼,李根池.小鼠甲醛致痛模型筛选中药牛膝的镇痛作用[J].中成药,1989,11(]0)：29.
[34]苗明三.薏苡仁多糖对环磷酸酰胺致免疫抑制小鼠免疫功能的影响[J].中国医药学报,2002,30(5).
[35]史玉芬,郑延彬.牛膝抗炎、抗菌作用的研究[J].中药通报,1988,13(7)：44.
[36]马子密,傅延龄.历代本草药性汇解[M].中国医药科技出版社,2002.
[37]陈长勋,李廷利,王树荣,等.中药药理学[M].上海科学技术出版社,2007.
[38]延卫东,王瑞君,何淡,等.黄芩苷药理作用研究进展[J].陕西中医.2002,23(12)：1127-1129.
[39]王玮,呈莹瑶,卢岩,等.野黄芩甙抗炎作用的实验研究[J].中国医科大学学报.2003,32(6)：503-504.
[40]Chen ZY,Su YL,Lac CW.et al.Endothelium dependent contraction and direct relaxation induced by baicalin in rat mesenteric artery[J].Eur J pharmarcol, 1999,374(1):41.
[41]于永芳,高瑞峰,李沈明.黄芩茎叶总黄酮对动脉粥术硬化早期病理改变的影响.中草药[J].2003,34(11)：1033-1035
[42]董昆山.现代临床中药学[M].中国中医药出版社,1998：533.
[43]阮金兰,赵钟祥,曾庆忠.赤芍化学成分和药理作用的研究进展[J].中国药理学通报,2003,19(9)：965-970.
[44]瞿佐发.赤芍的最新研究进展[J].时珍国医国药,2003,14(8)：310-311.
[45]Bhardwaj DK,Singh R.CA,1998,88:19048k.
[46]黄颂敏,刘先荣.肾脏疾病鉴别诊断与治疗学[M].人民军医出版社,2006.35.
[47]杨宝峰,苏定冯.药理学[M].人民卫生出版社,2006.216,283.
[48]陈香美,等.糖皮质激素治疗肾脏病的专家共识(第一版).2008年11月,北京.
[49]张宇明,闻家柱.大剂量谷胱甘肽治疗雷公藤多甙致药物性肝损害15例[J].中华现代内科学杂志.2005,2(3)：221.
[1]刘刚,马序竹,邹万忠,等.肾活检患者肾脏病构成十年对比分析[J].临床内科杂志,2004,21：834-838.
[2]Vriesendorp R,de Zeeuw D,de jong PE,et al.Reduction of urinary protein and prostaglandin E2 excretion in the nephritic syndrome by non-steroid antiinflammat-ory drugs[J].Clin Nephrol,1986,25:105-110.
[3]Heeg JE,de jong PE,van der Hem GK,et al.Reduction of proteinuria by angiotensin converting enzyme inhibition.Kidney Int[J],1987,32:78-83.
[4]Ballmer PE,Weber BK,Roy Chaudhury P,et al.Elevation of albumin synthesis rates in nephritic patients measured with [1-13C] leucinr[J].Kidney Int,1992,41:132-138.
[5]李丽英,于宏,潘辑圣,等.黄芪与当归对肾病综合征患者总体蛋白质代谢的影响[J].中华内科杂志,1995,34：670-672.
[6]Schultze G,Ahuja S,Faber U,et al.Gastrointestinal protein loss in the nephritic syndrome with 51Cr-albumin[J].Nephron,1980,25:227-230.
[7]Schrier RW,Fassett RG.A critique of the overfill hypothesis of sodium and water retention in the nephritic syndrome[J]. Kidney Int,1998,53:1111-1117.
[8]Vande Walle JG,Donckerwolcke RA,van Isselt JW,et al.Volume regulation in children with early relapse of minimal-change nephrosis with or without hypovol-aemic symptoms[J].Lancet,1995,346:148-152.
[9]Bernard DB.Extrarenal complications of the nephritic syndrome[J].Kidney Int,1988, 33:1184-1202.
[10]Short CD,Durtington PN,Mallick NP,et al.Serum and urinary highdensity lipoprotions in glomerular disease with proteinuria[J].Kidney Int,1986,29:1224-1228.
[11]陈香美,等.糖皮质激素治疗肾脏病的专家共识(第一版).2008年11月,北京.
[12]杨藻宸.医用药理学[M].北京：人民卫生出版社,2005,355-695.
[13]周仲瑛.中医内科学[M].北京：中国中医药出版社,2006.345-351
[14]李杰.肾性蛋白尿治疗刍议[J],长春中医学院学报,1995,11(12)：19.
[15]蔡红凯,李玉婷,乐才文.四妙散在肾病中的运用[J].中国中医急症,2006,15(10)：1162.
[16]于怀庆.辨证治疗慢性肾炎蛋白尿40例[J].陕西中医,2000,21(4)：155.
[17]师晶丽.肾小球疾病中医辨证分型与血脂关探讨[J].贵阳中医学院学报,1995,20(1)：32-33.
[18]管鹏声.肾病综合征治疗经验[J],云南中医学院学报,1996,19(4)：34.
[19]孙环宇.五子衍宗丸加减治疗肾病蛋白尿[J],山东中医杂志,2001,20(4)：249.
[20]张志忠.仙黄散治疗难治性肾病综合征蛋白尿[J],中国中医杂志,2002,11(3)：221.
[21]韩履祺,王琴.难治性肾病综合征从肝论治[J].2000,(2)：75.
[22]石景凉.中医药消除肾病综合征蛋白尿六法[J],河南中医,1999,19(3)：3.
[23]叶任高,李幼姬,刘冠贤,等.临床肾脏病学[M].北京：人民卫生出版社,2007.164-165.
[24]李月红.中西医结合治疗原发性肾病综合征的思路.2009年9月,天津.
[25]张道友,叶任高,李幼姬,等.成人原发性肾病综合征临床及实验系列研究成果综述[J].中山医科大学学报,1 999,20(2)：85.
[26]杨倩春.杨霓芝教授治疗难治性肾病综合征的临床经验[J].中国中两医结合肾病杂志,2003,4(9)：500-502.
[27]谢昆,叶任高,陈志英.中西医治疗成人复发性肾病综合征疗效观察[J].现代诊断与治疗,1998,9(1)：17-21.
[28]顾美华,李永玉,李小伟.中医中药为主治疗难治性肾病综合征60例[J].国医论坛,1992,7(2)：23-24.
[29]刘宏伟,时振声,林秀彬.难治性‘肾病综合征的中医治疗体会-附30例临床分析[J].天津中医,1992,(2)：2-3.
[30]赵兴兰,余仁欢.辨证分型治疗难治性肾病综合征[J].吉林中医药,1995,(3)：8-9.
[31]武俊斌,顾秀琰.戴恩来教授治疗难治性肾病综合征经验.亚太传统医药[J].2007,(1)：52-53.
[32]米杰,马宝良.四妙散在泌尿系统疾病中的临床应用[J].中国中西医结合肾病杂志,2009,10(12)：1094.